Labcorp reaffirmed its full-year 2026 financial guidance and outlined a long-term growth outlook through 2029, expecting compound annual revenue growth of 5% to 8% and adjusted EPS growth of 8.5% to 11.5%. The company emphasized strategic priorities including innovation in specialty testing, partnerships with health systems and pharma, personalized health solutions, and advanced technology adoption. Labcorp aims to expand operating margins and free cash flow alongside revenue growth, reinforcing its position in diagnostics and biopharma services. Investors can access a live webcast of the 2026 Investor Day for more details.
Flip Electronics has signed an authorized distribution agreement with Littelfuse to supply a wide range of Littelfuse's end-of-life, obsolete, aged, and excess electronic components. This partnership aims to support industries like industrial, milita...
Purepoint Uranium Group reported strong assay results from its 2026 winter drilling at the Nova Target, part of the Dorado Joint Venture with IsoEnergy. The highlight was a high-grade uranium intercept of 1.65% U₃O₈ over 0.3 metres at 390.4 metres de...
Apple shares recently dropped nearly 3%, prompting one investor to buy more, viewing the dip as a chance to invest in Apple's unique dual business model. Apple excels by selling popular hardware like iPhones and then generating high-margin recurring ...
Bitcoin ETFs like BlackRock's IBIT provide investors with price exposure to Bitcoin through traditional brokerage accounts without requiring direct ownership or self-custody of the cryptocurrency. ETFs charge annual management fees and trade during s...
Marubeni Corporation is recommended as a buy due to its efforts to improve returns on invested capital (ROIC) and reduce its weighted average cost of capital (WACC). The company is focusing on high-ROIC strategic businesses and applying stricter eval...
